Smith & Nephew plc Receives “Hold” Rating from Numis Securities Ltd (SN)
Smith & Nephew plc (LON:SN)‘s stock had its “hold” rating reaffirmed by equities research analysts at Numis Securities Ltd in a research note issued to investors on Friday. They currently have a GBX 1,000 ($16.98) price target on the stock. Numis Securities Ltd’s target price would indicate a potential downside of 6.10% from the company’s current price.
Shares of Smith & Nephew plc (LON:SN) traded up 3.80% during mid-day trading on Friday, hitting GBX 1065.00. The stock had a trading volume of 2,618,795 shares. Smith & Nephew plc has a 52-week low of GBX 737.50 and a 52-week high of GBX 1136.00. The stock’s 50-day moving average is GBX 1043.43 and its 200-day moving average is GBX 957.2. The company’s market cap is £9.510 billion.
A number of other analysts have also recently weighed in on SN. Analysts at Credit Suisse raised their price target on shares of Smith & Nephew plc from GBX 865 ($14.69) to GBX 890 ($15.11) in a research note on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Friday, July 25th. They now have a GBX 1,160 ($19.70) price target on the stock. Finally, analysts at BNP Paribas reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Thursday, July 24th. They now have a GBX 1,250 ($21.23) price target on the stock. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of GBX 973.50 ($16.53).
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.